HIMS is down 80%, creating a window of opportunity in the stock price for those interested in the business behind the chart. :
"Hims & Hers (HIMS) trades around $15–16 (as of March 3, 2026), down ~75–80% from its 2025 peak of $70.43.
Bullish highlights despite the dip:
2025 results: Revenue hit $2.35 billion (+59% YoY), with >2.5 million subscribers. Achieved profitability and strong cash flow from core areas (hair, ED, skin, mental health, hormones); non-GLP-1 revenue dominates in the U.S.
2026 guidance: Revenue $2.7–2.9 billion (+15–23% YoY), Adjusted EBITDA $300–375 million (11–13% margin).
2030 targets: At least $6.5 billion revenue and $1.3 billion Adjusted EBITDA — implying 20–25%+ CAGR over the coming years, fueled by new specialties (testosterone, menopause, labs), international expansion (e.g., Eucalyptus deal targeting $1B+ abroad), and personalized telehealth growth.
Valuation: Trades at a compressed multiple relative to long-term growth; analyst targets suggest meaningful upside.
GLP-1 headwinds (regulatory/competition) appear temporary, with diversification and platform strength supporting durable 20–30% growth potential through 2030. Classic "generational dip" setup for patient bulls in consumer health."
HIMS meets my growth criteria, price to sales criteria, and sentiment potential for a great opportunity. The Company is profitable and cashflow positive, and is earning close to the sp500 and bonds already, potentially earning more as a business soon.
Trade Idea- Im buying now for the long term, 2 to 10 years. If stocks moves 3x or more, I will trim to take most my cost basis out and keep the rest for free long term 10-20 years.
"Hims & Hers (HIMS) trades around $15–16 (as of March 3, 2026), down ~75–80% from its 2025 peak of $70.43.
Bullish highlights despite the dip:
2025 results: Revenue hit $2.35 billion (+59% YoY), with >2.5 million subscribers. Achieved profitability and strong cash flow from core areas (hair, ED, skin, mental health, hormones); non-GLP-1 revenue dominates in the U.S.
2026 guidance: Revenue $2.7–2.9 billion (+15–23% YoY), Adjusted EBITDA $300–375 million (11–13% margin).
2030 targets: At least $6.5 billion revenue and $1.3 billion Adjusted EBITDA — implying 20–25%+ CAGR over the coming years, fueled by new specialties (testosterone, menopause, labs), international expansion (e.g., Eucalyptus deal targeting $1B+ abroad), and personalized telehealth growth.
Valuation: Trades at a compressed multiple relative to long-term growth; analyst targets suggest meaningful upside.
GLP-1 headwinds (regulatory/competition) appear temporary, with diversification and platform strength supporting durable 20–30% growth potential through 2030. Classic "generational dip" setup for patient bulls in consumer health."
HIMS meets my growth criteria, price to sales criteria, and sentiment potential for a great opportunity. The Company is profitable and cashflow positive, and is earning close to the sp500 and bonds already, potentially earning more as a business soon.
Trade Idea- Im buying now for the long term, 2 to 10 years. If stocks moves 3x or more, I will trim to take most my cost basis out and keep the rest for free long term 10-20 years.
Trade ist aktiv
update, NVO made a deal with HIM, stock up over 40%
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.